Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BNXTF NASDAQ:GANX NASDAQ:MEIP OTCMKTS:PRVCF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNXTFBioNxt Solutions$0.36-19.6%$0.40$0.11▼$0.48$41.91M0.782,190 shs100 shsGANXGain Therapeutics$1.44-1.4%$1.74$0.89▼$3.19$43.90M0.11263,875 shs246,306 shsMEIPMEI Pharma$4.87-5.4%$3.25$1.46▼$9.00N/A0.363.00 million shs348,003 shsPRVCFPreveCeutical Medical$0.03+17.6%$0.03$0.01▼$0.03$12.33M0.3439,450 shs3,000 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNXTFBioNxt Solutions0.00%-13.54%-9.50%+4.65%+73.07%GANXGain Therapeutics-1.37%-14.79%-11.93%-30.10%+33.33%MEIPMEI Pharma-5.44%-27.74%+102.92%+138.73%+31.27%PRVCFPreveCeutical Medical+17.59%+6.28%+2.01%+5.39%+71.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics2.1343 of 5 stars3.63.00.00.02.20.00.6MEIPMEI Pharma1.6543 of 5 stars0.03.00.04.23.00.80.6PRVCFPreveCeutical MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNXTFBioNxt Solutions 0.00N/AN/AN/AGANXGain Therapeutics 3.17Buy$8.20469.44% UpsideMEIPMEI Pharma 0.00N/AN/AN/APRVCFPreveCeutical Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVCF, MEIP, GANX, and BNXTF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNXTFBioNxt Solutions$20K2,095.26N/AN/A($0.05) per share-7.24GANXGain Therapeutics$50K866.02N/AN/A$0.28 per share5.14MEIPMEI Pharma$65.30MN/A$5.66 per share0.86$4.96 per shareN/APRVCFPreveCeutical MedicalN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNXTFBioNxt Solutions-$3.88M-$0.04N/A∞N/A-19,165.00%N/A-663.55%N/AGANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)PRVCFPreveCeutical Medical-$860KN/A0.00∞N/AN/AN/A-603.63%N/ALatest PRVCF, MEIP, GANX, and BNXTF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GANXGain Therapeutics-$0.17N/AN/AN/AN/AN/A6/26/2025Q1 2025BNXTFBioNxt SolutionsN/A-$0.01N/A-$0.01N/AN/A5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/APRVCFPreveCeutical MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNXTFBioNxt SolutionsN/A0.150.15GANXGain Therapeutics0.052.222.22MEIPMEI PharmaN/A16.7816.78PRVCFPreveCeutical MedicalN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNXTFBioNxt SolutionsN/AGANXGain Therapeutics11.97%MEIPMEI Pharma52.38%PRVCFPreveCeutical MedicalN/AInsider OwnershipCompanyInsider OwnershipBNXTFBioNxt SolutionsN/AGANXGain Therapeutics7.18%MEIPMEI Pharma3.12%PRVCFPreveCeutical MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableGANXGain Therapeutics2030.07 million27.91 millionOptionableMEIPMEI Pharma100N/AN/AOptionablePRVCFPreveCeutical MedicalN/A570.65 millionN/ANot OptionablePRVCF, MEIP, GANX, and BNXTF HeadlinesRecent News About These CompaniesPreveCeutical Announces Rescheduled Date for Annual General and Special MeetingJuly 9, 2025 | newsfilecorp.comNPRVCF PreveCeutical Medical Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comPreveCeutical Appoints Dr. Francis Tavares as CTO to Enhance Drug Discovery EffortsJune 30, 2025 | tipranks.comPreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology OfficerJune 30, 2025 | newsfilecorp.comNPreveCeutical Announces Date for Annual General and Special MeetingJune 25, 2025 | newsfilecorp.comNPreveCeutical Announces Non-Brokered Private PlacementJune 11, 2025 | newsfilecorp.comNPreveCeutical Appoints Dr. Deepak Sampath as Corporate AdvisorJune 2, 2025 | tipranks.comPreveCeutical Appoints Stephen Glover as Corporate Advisor to Boost Strategic GrowthMay 26, 2025 | tipranks.comPreveCeutical Welcomes Stephen Glover as Corporate AdvisorMay 26, 2025 | newsfilecorp.comNPreveCeutical Completes Private Placement to Boost R&D EffortsMay 22, 2025 | tipranks.comPreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private PlacementMay 22, 2025 | newsfilecorp.comNPreveCeutical’s BioGene Launches New Website to Boost Digital EngagementMay 14, 2025 | tipranks.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc. ...May 14, 2025 | gurufocus.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative TherapiesMay 14, 2025 | newsfilecorp.comNPreveCeutical Closes Initial Tranche of Private Placement, Raising $590,001April 28, 2025 | tipranks.comPreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private PlacementApril 28, 2025 | newsfilecorp.comNPreveCeutical Upsizes Private Placement to Bolster Financial PositionApril 15, 2025 | tipranks.comPreveCeutical Announces Up-Sized Non-Brokered Private PlacementApril 14, 2025 | newsfilecorp.comNPreveCeutical Announces Update to Non-Brokered Private PlacementApril 2, 2025 | newsfilecorp.comNPreveCeutical Launches Private Placement to Raise $500,000April 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVCF, MEIP, GANX, and BNXTF Company DescriptionsBioNxt Solutions OTCMKTS:BNXTF$0.36 -0.09 (-19.56%) As of 07/31/2025 09:30 AM EasternBioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Gain Therapeutics NASDAQ:GANX$1.44 -0.02 (-1.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.36%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.MEI Pharma NASDAQ:MEIP$4.87 -0.28 (-5.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.03 +0.16 (+3.29%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.PreveCeutical Medical OTCMKTS:PRVCF$0.03 +0.00 (+17.59%) As of 08/1/2025 11:28 AM EasternPreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
